{
 "id": "prostate-cancer",
 "name": "Prostate Cancer",
 "aliases": [
  "Prostate cancer"
 ],
 "acronyms": [],
 "bodySystem": "cancer",
 "parent": null,
 "children": [
  "metastatic-castrate-resistant-prostate-cancer",
  "metastatic-prostate-cancer"
 ],
 "edition": "2026-11",
 "merkleRoot": "006ab9a329709cbe7f56a0e1a7c4a02f897655cdfecf9ca34d199690095adcb6",
 "builtFrom": "program.status and program.eligibility facts, grouped by the condition registry",
 "counts": {
  "open": 0,
  "limited": 0,
  "waitlist": 0,
  "closed": 4
 },
 "funds": [
  {
   "fund": "Prostate Cancer",
   "organization": "CancerCare",
   "status": "closed",
   "dateOnPage": null,
   "awardLevelUsd": null,
   "insuranceTypes": null,
   "pageSays": "The page marks the fund as not currently open for new enrollments (the fund row's own data-statuses attribute reads closed).",
   "readOn": "2026-11-08",
   "source": "https://www.cancercare.org/copayfoundation"
  },
  {
   "fund": "Prostate Cancer - Medicare Access",
   "organization": "HealthWell Foundation",
   "status": "closed",
   "dateOnPage": null,
   "awardLevelUsd": null,
   "insuranceTypes": null,
   "pageSays": "The page lists the fund as Closed.",
   "readOn": "2026-11-08",
   "source": "https://www.healthwellfoundation.org/disease-funds/"
  },
  {
   "fund": "Prostate cancer",
   "organization": "TotalAssist (Patient Advocate Foundation copay funds)",
   "status": "closed",
   "dateOnPage": null,
   "awardLevelUsd": 4000,
   "insuranceTypes": [
    "Medicaid",
    "Medicare",
    "TRICARE"
   ],
   "pageSays": "The page lists the fund as Closed.",
   "readOn": "2026-11-08",
   "source": "https://totalassist.org/funds/"
  },
  {
   "fund": "Prostate cancer health equity",
   "organization": "TotalAssist (Patient Advocate Foundation copay funds)",
   "status": "closed",
   "dateOnPage": null,
   "awardLevelUsd": 4000,
   "insuranceTypes": [
    "Medicaid",
    "Medicare",
    "TRICARE"
   ],
   "pageSays": "The page lists the fund as Closed.",
   "readOn": "2026-11-08",
   "source": "https://totalassist.org/funds/"
  }
 ],
 "drugsWhoseLabelNamesThisCondition": [
  {
   "ingredient": "APALUTAMIDE",
   "pages": [
    {
     "brand": "Erleada",
     "url": "https://omnirx.org/negotiated-drugs/erleada"
    }
   ],
   "labelSentence": "ERLEADA is indicated for the treatment of patients with Metastatic castration-sensitive prostate cancer (mCSPC) Non-metastatic castration-resistant prostate cancer (nmCRPC) ERLEADA is an androgen receptor inhibitor indicated for the treatment of patients ...",
   "labelContext": "indication",
   "labelSource": "https://api.fda.gov/drug/label.json?search=set_id:%22d1cda4f7-cb33-46ea-b9ac-431f6452b1a5%22&limit=1",
   "labelRead": "2026-11-10",
   "manufacturerPrograms": [
    {
     "name": "J&J Patient Assistance Foundation (JJPAF)",
     "url": "https://omnirx.org/assistance/johnson-and-johnson-pap",
     "programPageIsExternal": false,
     "inCurrentList": true,
     "note": null,
     "listKind": "Medicines in the Quick Reference Guide picker on the program page",
     "status": null,
     "statusRead": null
    }
   ],
   "medicareNegotiatedPrice": {
    "usd30DaySupply": null,
    "effective": "2028-01-01",
    "source": "https://www.cms.gov/initiatives/medicare-prescription-drug-affordability/overview/medicare-drug-price-negotiation-program/selected-drugs-negotiated-prices"
   }
  },
  {
   "ingredient": "ENZALUTAMIDE",
   "pages": [
    {
     "brand": "Xtandi",
     "url": "https://omnirx.org/negotiated-drugs/xtandi"
    }
   ],
   "labelSentence": "... castration-resistant prostate cancer (CRPC) • metastatic castration-sensitive prostate cancer (mCSPC) • non‑metastatic castration‑sensitive prostate cancer (nmCSPC) with biochemical recurrence at high risk for ...",
   "labelContext": "indication",
   "labelSource": "https://api.fda.gov/drug/label.json?search=set_id:%22b129fdc9-1d8e-425c-a5a9-8a2ed36dfbdf%22&limit=1",
   "labelRead": "2026-11-10",
   "manufacturerPrograms": [
    {
     "name": "Astellas Pharma Support Solutions",
     "url": "https://www.astellaspharmasupportsolutions.com/",
     "programPageIsExternal": true,
     "inCurrentList": true,
     "note": null,
     "listKind": "resource library product list for patients and caregivers",
     "status": null,
     "statusRead": null
    },
    {
     "name": "Pfizer RxPathways",
     "url": "https://omnirx.org/assistance/pfizer-rxpathways",
     "programPageIsExternal": false,
     "inCurrentList": true,
     "note": null,
     "listKind": null,
     "status": "limited",
     "statusRead": "2026-11-07"
    }
   ],
   "medicareNegotiatedPrice": {
    "usd30DaySupply": 7004,
    "effective": "2027-01-01",
    "source": "https://www.cms.gov/initiatives/medicare-prescription-drug-affordability/overview/medicare-drug-price-negotiation-program/selected-drugs-negotiated-prices"
   }
  },
  {
   "ingredient": "Capivasertib",
   "pages": [
    {
     "brand": "Truqap",
     "url": "https://omnirx.org/medicines/truqap"
    }
   ],
   "labelSentence": "PTEN-deficient metastatic androgen pathway modulation-naïve or -sensitive (mAPMN/S) prostate cancer • in combination with abiraterone and prednisone for the treatment of adult patients with metastatic androgen pathway modulation-naïve or -sensitive (mAPMN/S) ...",
   "labelContext": "indication",
   "labelSource": "https://api.fda.gov/drug/label.json?search=set_id:%22d698c106-2322-401e-b738-cbd83c843ecf%22&limit=1",
   "labelRead": "2026-11-10",
   "manufacturerPrograms": [
    {
     "name": "AZ&Me Prescription Savings Program",
     "url": "https://omnirx.org/assistance/astrazeneca-azandme",
     "programPageIsExternal": false,
     "inCurrentList": true,
     "note": null,
     "listKind": null,
     "status": "limited",
     "statusRead": "2026-11-06"
    }
   ],
   "medicareNegotiatedPrice": null
  },
  {
   "ingredient": "Darolutamide",
   "pages": [
    {
     "brand": "Nubeqa",
     "url": "https://omnirx.org/medicines/nubeqa"
    }
   ],
   "labelSentence": "... non-metastatic castration-resistant prostate cancer (nmCRPC).",
   "labelContext": "indication",
   "labelSource": "https://api.fda.gov/drug/label.json?search=set_id:%221a7cb212-56e4-4b9d-a73d-bfee7fe4735e%22&limit=1",
   "labelRead": "2026-11-10",
   "manufacturerPrograms": [
    {
     "name": "Bayer US Patient Assistance Foundation",
     "url": "https://www.patientassistance.bayer.us/en/about/bayer-products",
     "programPageIsExternal": true,
     "inCurrentList": true,
     "note": null,
     "listKind": "Bayer prescription medicines included in the program",
     "status": null,
     "statusRead": null
    }
   ],
   "medicareNegotiatedPrice": null
  },
  {
   "ingredient": "Leuprolide Acetate",
   "pages": [
    {
     "brand": "Lupron Depot",
     "url": "https://omnirx.org/medicines/lupron-depot"
    }
   ],
   "labelSentence": "VABRINTY is indicated for the treatment of advanced prostate cancer.",
   "labelContext": "indication",
   "labelSource": "https://api.fda.gov/drug/label.json?search=set_id:%22008776cc-83f1-4f8c-819b-6471425da15f%22&limit=1",
   "labelRead": "2026-11-10",
   "manufacturerPrograms": [
    {
     "name": "myAbbVie Assist",
     "url": "https://omnirx.org/assistance/abbvie-myabbvie-assist",
     "programPageIsExternal": false,
     "inCurrentList": true,
     "note": null,
     "listKind": "Available medicines (myAbbVie Assist)",
     "status": null,
     "statusRead": null
    }
   ],
   "medicareNegotiatedPrice": null
  },
  {
   "ingredient": "Olaparib",
   "pages": [
    {
     "brand": "Lynparza",
     "url": "https://omnirx.org/medicines/lynparza"
    }
   ],
   "labelSentence": "Prostate cancer • for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant ...",
   "labelContext": "indication",
   "labelSource": "https://api.fda.gov/drug/label.json?search=set_id:%22741ff3e3-dc1a-45a6-84e5-2481b27131aa%22&limit=1",
   "labelRead": "2026-11-10",
   "manufacturerPrograms": [
    {
     "name": "Cancer Drug Assistance (Multiple Programs)",
     "url": "https://omnirx.org/assistance/cancer-drug-assistance",
     "programPageIsExternal": false,
     "inCurrentList": true,
     "note": null,
     "listKind": null,
     "status": null,
     "statusRead": null
    },
    {
     "name": "AZ&Me Prescription Savings Program",
     "url": "https://omnirx.org/assistance/astrazeneca-azandme",
     "programPageIsExternal": false,
     "inCurrentList": true,
     "note": null,
     "listKind": null,
     "status": "limited",
     "statusRead": "2026-11-06"
    }
   ],
   "medicareNegotiatedPrice": null
  },
  {
   "ingredient": "Denosumab",
   "pages": [
    {
     "brand": "Prolia",
     "url": "https://omnirx.org/medicines/prolia"
    }
   ],
   "labelSentence": "Treatment of Bone Loss in Men Receiving Androgen Deprivation Therapy for Prostate Cancer Conexxence is indicated as a treatment to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy (ADT) for nonmetastatic prostate ...",
   "labelContext": "indication",
   "labelSource": "https://api.fda.gov/drug/label.json?search=set_id:%2239a0a789-778f-4695-b3a9-61643e6396cd%22&limit=1",
   "labelRead": "2026-11-10",
   "manufacturerPrograms": [],
   "medicareNegotiatedPrice": null
  },
  {
   "ingredient": "Relugolix",
   "pages": [
    {
     "brand": "Orgovyx",
     "url": "https://omnirx.org/medicines/orgovyx"
    }
   ],
   "labelSentence": "ORGOVYX is indicated for the treatment of adult patients with advanced prostate cancer.",
   "labelContext": "indication",
   "labelSource": "https://api.fda.gov/drug/label.json?search=set_id:%22077a92f6-9f1b-479a-87c7-c92b5db6aa9c%22&limit=1",
   "labelRead": "2026-11-10",
   "manufacturerPrograms": [],
   "medicareNegotiatedPrice": null
  }
 ],
 "fundsForRelatedCosts": [
  {
   "fund": "American Cancer Society Cancer Care Continuity Fund",
   "organization": "Patient Advocate Foundation",
   "status": "closed",
   "readOn": "2026-11-08",
   "source": "https://www.patientadvocate.org/connect-with-services/financial-aid-funds/"
  },
  {
   "need": "testing",
   "fund": "Cancer genetic and genomic testing",
   "organization": "TotalAssist (Patient Advocate Foundation copay funds)",
   "status": "open",
   "readOn": "2026-11-08",
   "source": "https://totalassist.org/funds/"
  },
  {
   "need": "home care",
   "fund": "Cancer Home Care Services",
   "organization": "HealthWell Foundation",
   "status": "open",
   "readOn": "2026-11-08",
   "source": "https://www.healthwellfoundation.org/disease-funds/"
  },
  {
   "need": "behavioral health",
   "fund": "Cancer-Related Behavioral Health",
   "organization": "HealthWell Foundation",
   "status": "closed",
   "readOn": "2026-11-08",
   "source": "https://www.healthwellfoundation.org/disease-funds/"
  },
  {
   "need": "pain management",
   "fund": "Cancer-Related Pain Management",
   "organization": "CancerCare",
   "status": "closed",
   "readOn": "2026-11-08",
   "source": "https://www.cancercare.org/copayfoundation"
  },
  {
   "need": "caregiver support",
   "fund": "CancerCare CAR-T Caregiver Assistance Fund",
   "organization": "CancerCare",
   "status": "closed",
   "readOn": "2026-11-08",
   "source": "https://www.cancercare.org/copayfoundation"
  },
  {
   "need": "caregiver support",
   "fund": "CancerCare Caregiver Financial Assistance Fund(s)",
   "organization": "CancerCare",
   "status": "closed",
   "readOn": "2026-11-08",
   "source": "https://www.cancercare.org/copayfoundation"
  },
  {
   "need": "clinical trial costs",
   "fund": "CancerCare Clinical Trial Financial Assistance Fund",
   "organization": "CancerCare",
   "status": "closed",
   "readOn": "2026-11-08",
   "source": "https://www.cancercare.org/copayfoundation"
  },
  {
   "need": "transportation",
   "fund": "CancerCare Gets You There - Transportation Assistance Fund(s)",
   "organization": "CancerCare",
   "status": "closed",
   "readOn": "2026-11-08",
   "source": "https://www.cancercare.org/copayfoundation"
  },
  {
   "need": "behavioral health",
   "fund": "Oncology Caregiver Behavioral Health Fund (Accepting phone applications only)",
   "organization": "HealthWell Foundation",
   "status": "open",
   "readOn": "2026-11-08",
   "source": "https://www.healthwellfoundation.org/disease-funds/"
  }
 ],
 "note": "Each status is what the fund page said on readOn. It is not an eligibility determination. We hold only the organizations we read; no fund here does not mean no fund exists.",
 "licence": "CC BY 4.0 for the OmniRx compilation"
}